AMPH
Amphastar Pharmaceuticals Inc

1,130
Mkt Cap
$1.41B
Volume
286,949.00
52W High
$37.66
52W Low
$20.39
PE Ratio
11.56
AMPH Fundamentals
Price
$26.07
Prev Close
$26.00
Open
$25.94
50D MA
$26.61
Beta
0.71
Avg. Volume
369,697.27
EPS (Annual)
$3.06
P/B
1.56
Rev/Employee
$360,930.47
Loading...
Loading...
News
all
press releases
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?
CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.
Zacks·5d ago
News Placeholder
More News
News Placeholder
Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives used a conference presentation to highlight the company's shift toward higher-value proprietary products, while also outlining near-term launch...
MarketBeat·5d ago
News Placeholder
Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Pacer Advisors Inc.
Pacer Advisors Inc. trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 98.2% during the third quarter, according to the company in its most recent 13F filing with...
MarketBeat·16d ago
News Placeholder
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) has earned a consensus recommendation of "Hold" from the eight research firms that are presently covering the company, MarketBeat.com...
MarketBeat·22d ago
News Placeholder
129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to the company in its most recent disclosure...
MarketBeat·23d ago
News Placeholder
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
Zacks·25d ago
News Placeholder
Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Squarepoint Ops LLC cut its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 67.0% during the second quarter, according to the company in its most recent...
MarketBeat·26d ago
News Placeholder
Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells 9,787 Shares of Stock
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, December 17th. The...
MarketBeat·1mo ago
News Placeholder
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
Zacks·1mo ago
News Placeholder
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to "Hold" at Barclays
Barclays upgraded Amphastar Pharmaceuticals to a "hold" rating in a research report on Monday...
MarketBeat·1mo ago
<
1
2
...
>

Latest AMPH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.